Becker's Healthcare January 10, 2024
Experts and industry analysts largely agree Eli Lilly’s new direct-to-consumer platform will increase access to patients who may benefit from its new anti-obesity drug Zepbound, but questions are being raised surrounding appropriate care coordination and the business model behind the offering.
Eli Lilly on Jan. 4 launched LillyDirect, a website that connects people with independent providers for obesity medications, including Zepbound. The new service also includes prescriptions for certain Lilly insulin products for diabetes patients and a migraine drug, as well as direct home delivery of its medications through third-party services. Mounjaro is not part of LillyDirect, though it may be added later, company CEO David Ricks told The Wall Street Journal.
For weight-loss prescriptions, the drugmaker is...
Today's Sponsors
Today's Sponsor